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Background: Experts recommend formulating a structured research question to guide the research design.
However, the basis for this recommendation has not been formally evaluated. The aim of this study was to
examine if a structured research question using the PICOT (Population, Intervention, Comparator, Outcome, Time-
frame) format is associated with a better reporting quality of randomized controlled trials (RCTs).
Methods: We evaluated 89 RCTs reports published in three endocrinology journals in 2005 and 2006, the quality
of reporting of which was assessed in a previous study. We examined whether the reports stated each of the five
elements of a structured research question: population, intervention, comparator, outcome and time-frame. A
PICOT score was created with a possible score between 0 and 5. Outcomes were: 1) a 14-point overall reporting
quality score (OQS) based on the Consolidated Standards for Reporting Trials; and 2) a 3-point key score (KS),
based on allocation concealment, blinding and use of intention-to-treat analysis. We conducted multivariable
regression analyses using generalized estimating equations to determine if a higher PICOT score or the use of a
structured research question were independently associated with a better reporting quality. Journal of publication,
funding source and sample size were identified as factors associated with OQS in our previous report on this
dataset, and therefore included in the model.
Results: A higher PICOT score was independently associated with OQS (incidence rate ratio (IRR) = 1.021, 95% CI:
1.012 to 1.029) and KS (IRR = 1.142, 95% CI: 1.079 to 1.210). A structured research question was present in 33.7% of
the reports and it was associated with a better OQS (IRR = 1.095, 95% CI 1.059-1.132) and KS (IRR = 1.530, 95% CI
1.311-1.786).
Conclusions: Better framing of the research question using the PICOT format is independently associated with
better overall reporting quality - although the effect is small - and better reporting of key methodologies.
Background
We recently found suboptimal quality of reporting of
RCTs in three general endocrinology journals and identi-
fied important deficiencies in the reporting of key metho-
dological items [1]. Poor quality of reporting of RCTs is
not limited to the endocrine literature. Similar findings
have been reported for RCTs published in leading general
medical journals and subspecialty journals [2-6].
Reporting deficiencies can reduce the confidence in
RCT results and hinder their applications in developing
clinical practice guidelines and conducting unbiased
meta-analyses. The Consolidated Standards of Reporting
Trials (CONSORT) group has been making efforts to
improve the transparency and quality of RCT reports
since 1996. They have published reporting guidelines and
updates, which are available at http://www.consort-state-
ment.org[7-9]. Journals which have adopted the CON-
SORT statement have shown some improvement in the
quality of reporting of their manuscripts, although the
magnitude of this improvement has been variable [10].
Finding predictors or determinants of quality of
reporting of RCTs could guide the triage of articles that
are worthwhile for busy clinicians who act as peer-
reviewers. Most importantly, it could also help to
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vious study, we found that journal of publication, type
o ff u n d i n ga n ds a m p l es i z ew e r es i g n i f i c a n t l ya s s o c i a t e d
with overall quality of reporting, where the assessment
of quality of reporting was based on 15 out of the 22
CONSORT items [1]. We could not find any variable
significantly associated with quality of reporting of key
methodological items - namely, allocation concealment,
blinding, and analysis by intention to treat principle [1].
A clear research question (RQ) is the starting point
for any research project because it guides the develop-
ment of the research design and protocol. Expert meth-
odologists have proposed the use of a structured
research question to guide this process [11]. A struc-
tured RQ about therapy should contain the following
five elements: population, intervention, comparator, out-
come, and time-frame. These elements are commonly
referred to by the acronym PICOT [11]. There are
many benefits of having a well-structured research ques-
tion which include increasing the likelihood of finding a
solution to the problem [12], enhancing the clarity of
the thought process in developing the protocol, inform-
ing the design, guiding analysis decisions, and ensuring
publication [13-15]. Whether the use of a structured RQ
is associated with better quality of reporting is
unknown. The aims of this study were to assess how the
PICOT format is used to frame research questions,
objectives or hypotheses based on reports of RCTs pub-
lished in general endocrinology journals and evaluate
the association between the presence of a structured RQ
using the PICOT format and the quality of reporting of
RCT reports.
Methods
Study design and setting
This is an analysis based on a systematic review of 89
RCTs published between January 2005 and December
2006 in three general endocrinology journals. We
selected the three general endocrinology journals with
the highest impact factor (IF) in 2006 as our source of
RCT reports. These are the Journal of Clinical Endocri-
nology and Metabolism (IF = 5.8), Clinical Endocrinology
(IF = 3.4) and the European Journal of Endocrinology (IF
= 3.1). Details on how we selected the studies are
described elsewhere [1]. Briefly, we included all parallel
design RCTs that addressed a question of treatment or
prevention. We excluded cross-over trials and trials eval-
uating pathophysiological mechanisms, pharmacokinetics
or drug tolerability as well as economic studies and trial
reports that had published their methods in a separate
publication. The selection process was carried out in
duplicate by two independent investigators in two
screening phases: title and abstract and full text. Investi-
gators resolved discrepancies by consensus.
Rating the reporting quality
Full details on how we measured the reporting quality
are available in our previous publication [1]. In our pre-
vious study, we chose 15 items from the revised CON-
SORT statement [7] to construct a 15-point overall
quality score (OQS). We chose the CONSORT criteria
because they are the accepted standards for reporting
R C T sa n dt h e yh a v eb e e ne n d o r s e db ym a n ym e d i c a l
journals and leading editorial organizations. We defined
quality of reporting as the extent to which the rationale,
method, conduct and results of the trial are reported.
Therefore, we adopted 15 CONSORT items pertaining
to the Introduction, Methods and Results sections for
our appraisal (Table 1). We chose these 15 items
because lack of their reporting has been associated with
higher level of bias [7]. We excluded the CONSORT
discussion section items because we considered them
too subjective to evaluate. We also excluded three key
methodological qualities for a separate assessment. For
this study, we additionally excluded the CONSORT item
on the description of the objective or research question
(item 6 in Table 1) as this is represented by PICOT, our
explanatory variable. We scored each item 1 if it was
reported and 0 if it was not clearly stated or definitely
not stated. Thus, the OQS had a possible value between
0 and 14. We note here that as a study quality score,
the OQS is a measure of the completeness of reporting
of 14 CONSORT items.
We also constructed a 3-point key score (KS) based
on three items that are highly important in avoiding
bias: allocation concealment, blinding and analysis
according to the intention to treat (ITT) principle
[16,17]. We scored each item 1 if it was present and 0 if
it was absent according to the definitions below. Thus,
the KS had a possible value between 0 and 3.
Allocation concealment was considered to be present if
one of the following allocation methods was reported: a)
centralized randomization, b) numbered coded vehicles,
and c) opaque, sealed and sequentially numbered envel-
opes. Blinding was considered to be present if at least two
groups were explicitly reported as blinded. The groups
considered for blinding included patients, caregivers, data
collectors, outcome assessors, data analysts and manu-
script writers. For studies in which blinding of patients
and caregivers was considered not feasible by the reviewer,
then, blinding was considered as present if at least one
specific group was explicitly reported as blinded.
As the term ITT is not used consistently by researchers
[18,19], we intended to capture how investigators actually
conducted the analysis instead of just checking whether
they stated performing an ITT analysis. For this purpose,
we examined the numbers presented in the text, tables
and figures of each article. We defined ITT analysis as
one where all patients were analyzed as part of the group
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whether they actually satisfied the entry criteria, the
treatment actually received, and subsequent protocol
deviations, participant compliance or withdrawal [18].
Rating the framing of the research question
We chose one paragraph from the introduction or meth-
ods section that best described the primary research ques-
tion, hypothesis or objective. In that paragraph, we
evaluated the framing of the RQ, regardless of whether it
was formulated as a research question, hypothesis or
objective. We examined whether the five elements of a
structured RQ were present in that paragraph. The five
elements were the type of patients or population relevant
to the question (P), the intervention (I), the comparative
intervention (C), the outcome of interest (O), and the time
horizon for measuring the outcome (T). We scored each
element 1 if it was present and 0 if it was absent. Thus, we
created a PICOT score with a possible score between 0
and 5. The score represents a measure of the completeness
of the description of the primary research question. The
concept of a structured RQ was originally described invol-
ving four elements (PICO) [13] and this was probably the
concept better known by investigators at the time of publi-
cation of the RCT reports under evaluation. Therefore, we
decided to qualify a report as providing a structured RQ
every time it described the four elements (Complete
PICO) in the context of the description of the primary
research question, study objective or research hypothesis.
Reports that did not describe these 4 elements (Incom-
plete PICO) did not qualify as providing a structured RQ.
Data abstraction
We used a standardized data abstraction form to extract
data from each article. Two reviewers (LR, CY) -blinded
to each other’s ratings-abstracted data independently. In
rating the framing of the RQ, the reviewers were blinded
to the OQS and KS for each article and they resolved
any disagreement through consensus. We used kappa
statistics to measure inter-rater agreement for each of
the five elements of the RQ. Kappa statistics for the KS
items have been reported in our previous study [1] and
varied from 0.55 to 0.65.
Statistical Analysis
We calculated the percentage of trials that clearly stated
each PICOT element and associated 95% confidence
interval (95% CI). We used Cohen’sK a p p a( )s t a t i s t i c
to calculate chance-adjusted inter-rater agreements. We
judged agreement as poor if  ≤ 02; fair if 0.21 ≤  ≤
0.4; moderate if 0.41 ≤  ≤ 0.6; substantial if 0.61 ≤  ≤
0.8; and good if  >0.8 [20].
We reported descriptive statistics on categorical data
as numbers (percentages) and scores (i.e., PICOT score,
OQS, and KS) as median (interquartile range [IQR]).
We evaluated whether a higher PICOT score was asso-
ciated with better reporting quality by conducting univari-
ate and multivariable regression analyses with OQS and
KS as the outcome variables. In our previous study on this
dataset, we found three variables, i.e., publication in the
JCEM, complete industrial funding and sample size, which
were significantly associated with better OQS. Therefore,
we included these variables in the multivariable models for
OQS and KS. We used generalized estimating equations
(GEE) [21] to account for the plausible correlation in the
reporting quality within the same journal. We modelled
within-journal correlation using an exchangeable working
correlation matrix. We assumed the Poisson distribution
for outcomes in GEE, as rating scores are non-negative
counts. The results were reported as exponents of the
coefficient estimates of the GEE analysis, which represent
Table 1 Overall Reporting Quality items
Item Description
1. Title or Abstract The title or the abstract states the study is a
randomized controlled trial.
2. Introduction Appropriate description of the scientific
background and explanation of the rationale.
Methods:
3. Participants Eligibility criteria for participants are clearly
described.
4. Interventions Precise details of the interventions intended
in each group are provided.
5. Outcomes Clear definition of primary and secondary
outcome measures is provided.
6. Objectives Specific objectives or research question or
hypotheses are stated.
7. Sample size Clear description on how the sample size
was determined is given.
8. Randomization
sequence generation
The method used to generate the random
allocation sequence is stated.
9. Randomization
implementation
The separation of generator of the allocation
sequence and executor is described.
10. Statistical methods Statistical methods used to compare groups
for primary outcomes, subgroup analyses or
adjusted analyses were properly described.
Results:
11. Participants flow Number of participants randomly assigned,
receiving intended treatment, completing
the study protocol, and analyzed for primary
outcome are given.
12. Recruitment Dates defining the periods of recruitment
and follow-up are provided.
13. Baseline data Baseline demographic and clinical




For each primary and secondary outcome, a
summary of results for each group and the
estimated effect size and its precision (e.g.,
95% CI) is provided.
15. Adverse events All important adverse events or side effects
in each intervention group are described.
* Item 6 (Objectives) was excluded from OQS.
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January 2005 to December 2006. Using the same statistical
approach as above, we also conducted univariate and mul-
tivariable regression analyses to determine whether the
use of a structured RQ (complete PICO) was associated
with a better OQS and KS. Variables were considered to
be statistically significant at alpha = 0.05. We conducted
all analyses using SAS 9.0 (Cary, NC).
Results
Framing of the research question
For the rating of the individual components of the RQ,
the  inter-rater agreement estimate was 0.54 (95% CI:
0.32, 0.77) for patients, 0.52 (95% CI: 0.15, 0.88) for
intervention, 0.87 (95% CI: 0.59, 0.87) for comparator,
0.20 (95% CI: 0.10, 0.30) for outcome, and 0.60 (95% CI:
0.41, 0.78) for time-frame. The median PICOT score
was 3 (IQR = 1). The percentage of articles that
reported each element of the primary RQ is provided on
Table 2. Patients, intervention and outcome were often
adequately described. However, half of the reports did
not describe the comparison intervention and a minority
described the study time frame. A complete description
of an ideal PICOT RQ was present in 16 out of the 89
reports (18.0%). A structured RQ (Complete PICO) was
present in 30 reports (33.71%).
Association between framing of the research question
and reporting quality
Tables 3 and 4 display the results of the univariate and
multivariable analyses of factors associated with OQS
and KS, respectively. A higher PICOT score was signifi-
cantly associated with a higher OQS (Table 3) and KS
(Table 4) in both univariate and multivariable analyses.
After adjusting for journal of publication, sample size
and funding source, each point increase in PICOT score
was significantly associated with a 2.1% increase in the
OQS and a 14.2% increase in the KS.z
As shown on Tables 5 and 6, the use of a structured
RQ (complete PICO) was also significantly associated
with better overall reporting quality (Table 5) and better
reporting of key quality elements (Table 6). After adjust-
ing for confounding variables, the presence of a struc-
tured RQ was associated with a 9.5% increase in the OQS
and a 53.0% increase in KS. The association between the
reporting of individual PICOT elements and OQS is
available as an additional file (additional file 1).
Discussion
We evaluated the prevalence of the use of the PICOT
format in framing the RQ in a sample of articles pub-
lished in three general endocrinology journals in 2005
and 2006. The framing of the RQ was usually incom-
plete and unclear, with only one-third of the reports
using a structured approach based on the PICOT for-
mat. These observations are consistent with a recent
Table 2 Frequency of description of each PICOT element
All articles n = 89
Element of the research question n % 95% CI
P: Patients 73 82 74 - 90
I: Intervention 83 93 88 - 98
C: Comparator 47 52 42 - 63
O: Outcome 65 73 63 - 82
T: Time 26 29 19- 38
Complete PICOT 16 18 10 - 27
Complete PICO 30 33 24 - 44
CI: Confidence interval
Table 3 Association between PICOT score and overall reporting quality
Independent Variable Median Q1-Q3 Multivariable Model Univariate Models
OQS
a IRR 95% CI p value IRR 95% CI p value
PICOT 9 8 - 10 1.021
b 1.012 - 1.029 < 0.0001 1.018 1.006 - 1.029 0.0032
Funding Source
Others
c 98 - 1 1 1 - - 1 - -
Completely funded by industry 10 9 - 10 1.022 0.999 - 1.046 0.0638 1.058 1.010 - 1.108 0.0177
Journal of Publication
Others
c 97 - 1 0 1 - - 1 - -
J Clin Endocrinol Metab 9 8 - 11 1.055 0.985 - 1.130 0.1280 1.074 0.986 - 1.171 0.1027
Sample Size 9 8 - 10 1.073
d 1.026 - 1.123 0.0020 1.095 1.011 - 1.185 0.0250
Abbreviations: OQS, Overall quality score; Q1, quartile 1; Q3, quartile 3; IRR, incidence rate ratio; 95% CI, 95% confidence interval; GEE, generalized estimating
equations; RCTs, randomized controlled trials.
a Maximum possible score = 14
b The value is an expression of the change in the average of the OQS due to one unit increase in PICOT score.
c Reference category
d The sample size variable was log(10) transformed. The value is an expression of the change in the average of the OQS due to one unit increase in sample size
in the log scale.
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of the studies did not fully apply the PICOT approach
in reporting the research question [13].
To the best of our knowledge, this is the first study
assessing the association between the framing of the RQ
and RCT reporting quality. Our results consistently indi-
cate a significant association between the completeness
of the RQ description and quality of reporting. We
found that the presence of a structured RQ is signifi-
cantly associated with a 9.5% increase in the OQS and a
53.0% increase in KS.
A bigger sample size, complete industry funding and
publication in the Journal of Clinical Endocrinology and
Metabolism were also significantly associated with overall
reporting quality but not with the report of key methodo-
logical items. It is plausible that part of the variation of the
quality of reporting between RCT reports can be explained
by other variables such as awareness of the CONSORT
statement by authors, adoption of CONSORT by journals
and availability of advice from a methodological expert
when planning an RCT. However, testing these hypotheses
was out of the scope of our study.
Table 4 Association between PICOT score and reporting of key quality elements
Independent Variable Median Q1-Q3 Multivariable Model Univariate Models
KS
a IRR 95% CI p value IRR 95% CI p value
PICOT 0 0 - 1 1.142
b 1.079 - 1.210 < 0.0001 1.142 1.058 - 1.232 0.0006
Funding Source
Others
c 00 - 1 1 - - 1 - -
Completely funded by industry 1 0 - 1 1.074 0.747 - 1.544 0.7013 1.112 0.761 - 1.623 0.5834
Journal of Publication
Others
c 00 - 1 1 - - 1 - -
J Clin Endocrinol Metab 0 0 - 1 0.881 0.533 - 1.455 0.6205 0.924 0.515 - 1.658 0.7919
Sample Size 0 0 - 1 1.255
d 0.936 - 1.684 0.1292 1.222 0.922 - 1.619 0.1623
Abbreviations: KS, Key score; Q1, quartile 1; Q3, quartile 3; IRR, incidence rate ratio; 95% CI, 95% confidence interval; GEE, generalized estimating equations; RCTs,
randomized controlled trials.
a Maximum possible score = 3
b The value is an expression of the change in the average of the key score due to one unit increase in PICOT score.
c Reference category
d The sample size variable was log(10) transformed. The value is an expression of the change in the average of the key score due to one unit increase in sample
size in the log scale.
Table 5 Association between a structured research question and overall reporting quality
Independent Variable Median Q1-Q3 Multivariable Model Univariate Models
OQS1
a IRR 95% CI p value IRR 95% CI p value
Structured RQ
Not complete PICO
c 97 - 1 0 1 - - 1 - -
Complete PICO 10 9 - 11 1.095 1.059 - 1.132 < 0.0001 1.104 1.084 - 1.125 < 0.0001
Funding Source
Others
c 98 - 1 1 1 - - 1 - -
Completely funded by industry 10 9 - 10 1.256 1.006 - 1.046 0.0113 1.074 0.986 - 1.171 0.1027
Journal of Publication
Others
c 97 - 1 0 1 - - 1 - -
J Clin Endocrinol Metab 9 8 - 11 1.039 0.962 - 1.121 0.3325 1.074 0.986 - 1.171 0.1027
Sample Size 9 8 - 10 1.066
d 1.012 - 1.123 0.0169 1.095 1.011 - 1.185 0.0250
Use of a structured RQ is defined as the reporting of complete PICO
Abbreviations: OQS, Overall quality score; Q1, quartile 1; Q3, quartile 3; IRR, incidence rate ratio; 95% CI, 95% confidence interval; GEE, generalized estimating
equations; RCTs, randomized controlled trials.
a Maximum possible score = 14
b The value is an expression of the change in the average of the OQS due to one unit increase in PICOT score.
c Reference category
d The sample size variable was log(10) transformed. The value is an expression of the change in the average of the OQS due to one unit increase in sample size
in the log scale.
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systematic way to construct the study question to aid
the search for valid answers [22]. In general, a struc-
tured RQ can guide the literature search, protocol devel-
opment and the conduct of a study. The explicit
statement of the five PICOT elements prompts the
investigator to think about the design to use and to con-
sider the balance between the research question and the
feasibility to answer it [22]. This also forms the basis for
the recommendation by experts in clinical epidemiology
to use a structured approach when formulating research
questions [11]. The Cochrane collaboration also advo-
cates the same approach in formulating research ques-
tions for their systematic reviews [23].
There are several limitations to our study. First, we did
not measure RCT methodological quality directly, as we
did not verify the information from the authors or their
protocols. Therefore, the quality of reporting should be
t a k e no n l ya sas u r r o g a t eo ft r u em e t h o d o l o g i c a lq u a l i t y
since important methodological detail may be omitted
from published reports[24,25]. In addition, some of the
items of the OQS explicitly assessed the completeness of
reporting - as a measure of reporting quality-rather than
the adequacy of the methods. On the other hand, the KS
can be considered a better indicator of methodological
quality since the three elements directly relate to the ade-
quacy of the methods used in each trial. The presence of a
stronger association with KS as compared to OQS suggests
that the use of a structured RQ could be associated with
better methodological quality. Second, our reporting
quality scores are not validated. There are more than 25
quality assessment scales, but most of them have not been
rigorously tested for validity and reliability [26]. Our OQS
s c o r ei sm a i n l yam e a s u r eo ft h ec o m p l e t e n e s so fr e p o r t i n g .
We based our score on the CONSORT criteria because
they are the most accepted standards for reporting RCTs
and have been widely endorsed by many clinical journals
and editorial organizations. Third, our analyses rely on
quality scores, which can be problematic [27-31]. Problems
with scales relate to both the choice of elements to include
in a score and how these elements should be weighted
[28,29]. Different methods to create the scores may lead to
different results when the scores are used in a particular
analysis. Several studies have shown a lack of agreement
between scores or scales in separating studies into low and
high quality and no scale has been found to be the best at
validly measuring quality [27,29,31]. This suggests that dif-
ferent scales are probably measuring different constructs
and it can be difficult to assign a meaning to a particular
quality score. Therefore, evaluating the quality of RCTs for
systematic reviews by analyzing quality items individually is
often considered a more preferred approach than relying
on combining the information in a single numerical value.
This approach may allow assigning different levels of
importance to individual quality items depending on the
context of the particular trial [28]. To avoid the limitations
of using quality scores, we could have conducted an analy-
sis of the association between the use of a structured RQ
and the reporting of each individual key element. However,
our study lacked of statistical power for such analysis as
Table 6 Association between a structured research question and reporting of key quality elements
Independent Variable Median Q1-Q3 Multivariable Model Univariate Models
KS
a IRR 95% CI p value IRR 95% CI p value
Structured RQ
Not complete PICO
c 00 - 1 1 - - 1 - -
Complete PICO 1 0 - 1 1.530 1.311 - 1.786 < 0.0001 1.510 1.398 - 1.632 < 0.0001
Funding Source
Others
c 00 - 1 1 - - 1 - -
Completely funded by industry 1 0 - 1 1.088 0.775 - 1.528 0.6249 1.112 0.761 - 1.623 0.5834
Journal of Publication
Others
c 00 - 1 1 - - 1 - -
J Clin Endocrinol Metab 0 0 - 1 0.808 0.466 - 1.400 0.4473 0.924 0.515 - 1.658 0.7919
Sample Size 0 0 - 1 1.216
d 0.876 - 1.689 0.2421 1.222 0.922 - 1.619 0.1623
Use of a structured RQ is defined as the reporting of complete PICO
Abbreviations: KS, Key score; Q1, quartile 1; Q3, quartile 3; IRR, incidence rate ratio; 95% CI, 95% confidence interval; GEE, generalized estimating equations; RCTs,
randomized controlled trials.
a Maximum possible score = 3
b The value is an expression of the change in the average of the key score due to one unit increase in PICOT score.
c Reference category
d The sample size variable was log(10) transformed. The value is an expression of the change in the average of the key score due to one unit increase in sample
size in the log scale.
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we opted for using the OQS and the KS. Caution should
therefore be taken in assigning a specific meaning to each
of our scores. The OQS is merely a measure of complete-
ness of reporting. The KS combines the information on the
use of allocation concealment, blinding and intention to
treat analysis. These items have been shown to be asso-
ciated with bias [16,17]. Fourth, the framing of PICOT is
itself an aspect of reporting quality. To avoid this problem,
at least in part, we excluded the item related to description
of the objectives or RQ from our OQS. Finally, the inclu-
sion of only general endocrinology journals may affect the
generalizability of our results. Our findings would need to
be confirmed by a similar and larger study applied to a
broader sample of RCT reports in other specialties and
also in leading general medical journals. In spite of these
limitations, we think our results have good internal validity.
We used a standardized evaluation instrument, two
reviewers independently performed the selection and
abstraction processes, and disagreements were always
resolved by consensus.
Conclusions
Our study findings show that the use of the PICOT format
to structure the RQ in RCT reports published in general
endocrinology journals over 2005-2006 was low. We also
found a small association between the use of a structured
RQ based on the PICOT format and a better overall
reporting quality of RCTs. The effect on key methodolo-
gies was more pronounced. It is important to recognize
that while poor reporting does not necessarily mean poor
design or conduct of a study, the quality of reporting is
routinely used by researchers as a proxy for study quality
in systematic reviews. An examination of a broader sample
of studies, including other areas of medicine, would be
necessary to confirm our results. The main implication of
this study is that the researchers should pay attention to
proper framing of the research question - they should con-
sider using a structured approach such as the PICOT for-
mat to frame it as this is likely to determine how the study
is designed, conducted and ultimately reported.
Additional file 1: Association between the reporting of individual
PICOT elements and overall reporting quality (OQS). The table shows
the association between the reporting of each individual PICOT element
and OQS expressed as incidence rate ratio (IRR). In the multivariable
analysis, there was a statistically significant negative association between
the reporting of the intervention and the comparator in the research
question and OQS. Conversely, there was a statistically significant positive
association between the reporting of the time frame in the research
question and OQS. The magnitude of all these associations was small.
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